XOMAP
XOMA Corporation NASDAQ$25.24
Mkt Cap $304.9M
52w Low $25.14
2.1% of range
52w High $30.00
50d MA $25.92
200d MA $26.20
P/E (TTM)
16.5x
EV/EBITDA
37.0x
P/B
4.4x
Debt/Equity
1.3x
ROE
37.8%
P/FCF
168.3x
RSI (14)
—
ATR (14)
—
Beta
0.68
50d MA
$25.92
200d MA
$26.20
Avg Volume
1.9K
About
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stag…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.11 | 0.26 | +327.0% | 25.80 | +0.3% | -0.2% | -0.8% | -0.8% | -0.8% | -0.8% | +0.2% | — |
| Nov 12, 2025 | AMC | -0.04 | 0.78 | +2050.0% | 26.35 | -0.3% | +0.2% | +0.2% | +0.6% | +0.6% | +0.9% | +1.5% | — |
| Aug 15, 2025 | AMC | -0.15 | 0.61 | +508.7% | 25.65 | +0.2% | +0.2% | +0.2% | +1.0% | +0.8% | +0.9% | +3.3% | — |
| May 13, 2025 | AMC | -0.24 | 0.20 | +183.2% | 25.43 | +0.0% | -0.1% | +0.8% | +0.8% | -0.1% | -0.1% | +0.6% | — |
| Mar 17, 2025 | AMC | -0.29 | -0.33 | -16.5% | 25.56 | +0.7% | +0.1% | +0.1% | +0.1% | +0.8% | +0.3% | +2.1% | — |
| Nov 7, 2024 | AMC | — | -1.47 | — | 25.80 | +0.0% | +0.0% | -0.5% | -0.5% | -0.4% | +0.7% | +0.2% | — |
| Aug 13, 2024 | AMC | — | 0.92 | — | 25.22 | -0.4% | +0.3% | +0.2% | +0.3% | -0.1% | +0.1% | +1.4% | — |
| May 9, 2024 | AMC | — | -0.74 | — | 25.09 | +0.0% | +0.0% | +0.3% | +0.3% | +0.7% | +0.8% | +1.7% | — |
| Mar 8, 2024 | AMC | — | -1.75 | — | 25.13 | +0.0% | +0.0% | -0.9% | +0.7% | -0.5% | -0.4% | -1.3% | — |
| Mar 6, 2024 | AMC | — | -0.48 | — | 25.10 | -0.7% | -1.0% | +0.1% | +0.1% | -0.8% | +0.8% | -1.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.53 | $23.55 | +0.1% | +0.1% | +0.9% | +2.0% | +2.0% | +3.1% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.22 | $24.22 | +0.0% | -0.7% | -0.4% | -0.5% | +0.1% | -0.7% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.77 | $24.09 | +1.3% | +0.6% | +0.5% | +0.3% | +1.4% | +1.8% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.65 | $23.54 | -0.5% | -0.5% | +0.2% | +0.2% | +0.5% | +1.1% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.00 | $24.88 | -0.5% | +0.0% | -1.5% | -1.0% | -3.5% | -3.3% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.07 | $26.13 | +0.2% | +0.2% | +0.2% | +0.3% | -0.1% | +0.4% |
| Sep 8 | Aegis Capital | Maintains | Buy → Buy | — | $26.43 | $26.40 | -0.1% | +0.6% | +0.2% | +0.8% | +1.5% | +1.6% |
| Sep 6 | Wedbush | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Jun 29 | Aegis Capital | Maintains | Buy → Buy | — | $26.05 | $25.92 | -0.5% | +0.5% | +1.9% | +1.2% | +0.3% | -0.2% |
| Sep 4 | Wedbush | Upgrade | Neutral → Outperform | — | — | — | — | — | — | — | — | — |
Recent Filings
8-K
XOMA ROYALTY CORP - XOMA 8 5/8 PERP -- 8-K Filing
Legendarily XOMA Royalty shareholders will receive cash and contingent value rights tied to RemainCo LLC interests in the merger, providing potential future payments beyond immediate consideration.
Apr 27
8-K
XOMA ROYALTY CORP - XOMA 8 5/8 PERP -- 8-K Filing
XOMA Royalty's perpetual preferred stock offer expired on February 6, 2026, without extension, meaning investors who didn't accept the offer by the deadline will not receive the 8.625% coupon securities.
Apr 27
Data updated apr 29, 2026 1:34am
· Source: massive.com